Bio-Rad Launches Easy-to-Use PureBlu™ Nuclear Staining Dyes

Date: 
2014-12-11

Hercules, CA — December 11, 2014 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of its PureBlu™ Nuclear Staining Dyes, high purity formulations that simplify nuclear staining for fluorescence imaging experiments.

In cell imaging experiments, DNA binding dyes are used to locate a cell’s nucleus. Current offerings of the most commonly used dyes, DAPI and Hoechst 33342, usually require time-consuming weighing and/or multiple tedious dilution steps.

Bio-Rad’s PureBlu Nuclear Staining Dyes are high purity, pre-aliquoted formulations of such traditional chemistries for cell imaging experiments. These dyes eliminate the need for weighing and require only a single dilution step upon resuspension. PureBlu DAPI is the ideal option for fixed samples, while Bio-Rad’s PureBlu Hoechst 33342 is recommended for live cell samples, as it has greater cell permeability and reduced toxicity compared to DAPI.

VivaFix allows efficient identification of live and dead cells in fixed and unfixed samples
PureBlu Nuclear Staining Dyes are ready for use after a simple resuspension and single dilution step.

Additional benefits of the PureBlu Nuclear Staining Dyes include:

  • High quality results — high purity formulation (>95%) suitable for challenging experiments
  • Ease of use — 5-vial pre-aliquoted format ensures that only the amount required is reconstituted to avoid wasting reagents
  • Flexibility — can be easily combined with other stains and dyes for multicolor imaging experiments

PureBlu Nuclear Staining Dyes are compatible with the ZOE™ Fluorescent Cell Imager and other imaging systems with UV excitation sources.

Visit www.bio-rad/PureBlupr to learn more about the PureBlu Nuclear Staining Dyes.

About the Cell Biology Portfolio
The cell biology product portfolio from Bio-Rad Laboratories comprises solutions for researchers conducting experiments that involve cell culture, cellular imaging, and cell analysis. Bio-Rad is a well-established provider of transfection tools, particularly through its line of Gene Pulser® Electroporation Systems. The company has expanded its cell biology offerings to include the S3e™ Cell Sorter, the ZOE™ Fluorescent Cell Imager, and the TC20™ Automated Cell Counter. These instruments are supported by a suite of flow cytometry and fluorescent cell imaging reagents, including ReadiLink Antibody Labeling Kits. In addition, more than 10,500 antibodies and associated kits and accessories are available for various cell biology applications from AbD Serotec®, a Bio-Rad company. Visit www.bio-rad.com/lifescience for more information.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of products for life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and industry customers through its global network of operations. The company employs more than 7,800 people worldwide and had revenues exceeding $2.1 billion in 2013. Visit us at www.bio-rad.com.

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

For more information contact:
Steve Kulisch
Bio-Rad
510-741-6688
Steve_Kulisch@bio-rad.com

Ken Li
Chempetitive Group
312-997-2436 x 112
kli@chempetitive.com